Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

(MedPage Today) — ORLANDO — In a phase III trial with potential practice-changing implications, the non-covalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in chronic lymphocytic leukemia…